ClinicalTrials.gg
Active, not recruitingNCT04902352Updated Nov 18, 2025

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

An interventional study of No Periadventitial dissection of the SMA and Periadventitial dissection of the SMA in Pancreatic Adenocarcinoma, sponsored by University Hospital Birmingham NHS Foundation Trust. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by University Hospital Birmingham NHS Foundation Trust · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 177 studies in Pancreatic Neoplasms with a site in United Kingdom — 42 open to participants now, 58 under way, 11 of them phase 3. Pancreatic Neoplasms · United Kingdom.

Planned enrollment
77th of 134
102 · median 120
Started
2021
with 8 others
No phase
13 of 177
5 open now
Primary completion
2026-10
later than 12 of 57 live
Registered
123rd of 177
by date

Among the 177 studies in Pancreatic Neoplasms with a site in United Kingdom, this one is the 77th largest by planned enrollment of the 134 interventional ones that give a count, is one of 9 that started in 2021, is one of 13 with no phase, reaches primary completion later than 12 of the 57 other live ones, and was the 123rd registered.

Pancreatic Neoplasms

3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,006 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

42 of the 177 studies in Pancreatic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Pancreatic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been proposed as an effective method of achieving R0 margins. There is lack of standardisation of the proposed technique and no grade 1 evidence to support routine use of this technique.

The goal of this randomised controlled trial is to investigate the role of routine peri-adventitial dissection on the SMA margin status.

Read the detailed description

Pancreatic cancer is the 4th cause of cancer death in Europe. With the existing treatments the overall 5-year survival remains 8%. For patients with non-metastatic disease, many are conventionally judged unresectable with just 10-20% eligible for upfront surgery and a 5-year survival of 10-30%. Microscopically positive margins (R1) have been associated with poorer survival of patients undergoing pancreaticoduodenectomy. The incidence of R1 varies between 16-79% in the published literature and the median survival for patients undergoing R0 resections is between 19-21 months versus 9-13 months for patients undergoing R1. Therefore, to investigate strategies to decrease the rate of R1 resection is crucial to significantly improve the patient survival1.

The SMA margin is positive in 47-77% of these resections, even when the margin is "clear" on the pre-operative staging CT2,4. Many different techniques are in practice and have been described for this part of the pancreaticoduodenectomy procedure, including the use of diathermy and ties, energy devices such as Ligasure, and staplers. The main denominator is staying close to the SMA and removing the so called "mesopancreas"3.Peri-adventitial arterial dissection is a technique that has been a commune practise in several pancreatic centres and has been proposed as an effective surgical technique to achieve R0 margins. On the other hand, SMA dissection may theoretically increase the risk of acute haemorrhage, vascular injury, and thrombosis, development of pseudo-aneurysms or persistent chyle leak due to the extensive lymphoneural dissection. Furthermore, the published evidence reveal variability in the definition of a "positive margin", as well as the lack of accurate description of the surgical technique in the majority of the studies, with only about 25% of the studies reporting the use of the technique4. Moreover, none of the published studies have documented standardisation in the use of the technique with regards to the extent of the periadventitial dissection on the SMA, longitudinally and circumferentially.

In the University Hospitals of Birmingham NHS Trust, pancreatic surgery is centralised in Queen Elizabeth Hospital. Peri-adventitial dissection is selectively performed in cases where there is a close relation of the tumour to the arteries in an effort to achieve an R0 resection. Routine practice of peri-adventitial dissection during pancreaticoduodenectomy for resectable tumours has been performed in a subset of patients based on surgeon's preference. The results suggest a R1 rate of 20%, with SMA margin positivity 5%, compared to a rate of 44% margin positivity within the unit, with 54% SMA R1 rate. Furthermore, complication rates are comparable to the average described by the unit's results and published literature (20.8% of grade B and above complications as per the Clavien-Dindo classification). More specifically, there have been no incidences of vascular related injury or complication related to the technique; or persistent chyle leak (one episode of chyle leak grade A recorded that was managed conservatively).

The goal of this prospective study is to investigate the role of routine peri-adventitial dissection on the SMA margin status. Primary outcome is SMA margin status. Secondary outcomes are: length of stay, complications, overall survival, disease free survival and adjuvant treatment uptake.

This will be a two arm, randomised 1:1 (periadventitial dissection : no periadventitial dissection) study. A pilot phase will determine feasibility to proceed with the rest of the trial and to determine:

  1. Feasibility of patient recruiting and randomisation
  2. Feasibility and reproducibility of the technique
  3. Feasibility of use of intraoperative photography
  4. Intraoperative and postoperative complication rate and severity (Clavien-Dindo classification)
  5. Positive SMA margin status rate

    Feasibility criteria to be met in order to proceed with the rest of the trial:

  6. Recruitment of at least 20 patients in 6 months (both arms)
  7. Periadventitial dissection technique to be performed in at least 80% of the randomised patients to that arm as documented by intraoperative photography
  8. Increase in the complication rate no more than 10%

For the full trial a sample size of 51 patients per arm has been based on a margin positivity of 44%, based on the unit's results, and expected 60% reduction (expected R1 18%) at power 80% (type A error 0.05).

03

Conditions studied

  • Pancreatic Adenocarcinoma

Keywords

  • pancreatic cancer
  • SMA dissection
  • Superior mesenteric artery
  • margin status
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult (≥ 18 years old) patients with a non- (based on NCCN definition) on imaging pancreatic tumour of the head or uncinate process treated with a pancreaticoduodenectomy

Exclusion criteria

Exclusion Criteria:

  1. All paediatric patients (\< 18 years old)
  2. Patients that cannot provide consent
  3. All borderline, locally advanced and pancreatic tumours on imaging (based on NCCN criteria)
  4. All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma
  5. All patients with benign disease or dysplasia with no evidence of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Periadventitial dissection

    For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process.

    Procedure: Periadventitial dissection of the SMA

  • Active comparator
    NO periadventitial dissection

    For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact

    Procedure: No Periadventitial dissection of the SMA

Interventions

  • ProcedureNo Periadventitial dissection of the SMA

    lymphoneural tissue around SMA left intact

  • ProcedurePeriadventitial dissection of the SMA

    For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.

06

What researchers measure

Primary outcomes

  1. SMA margin status

    Rate of R0 resection (defined as no tumour within 1mm from the SMA margin)

    Time frame: Recorded at histological examination estimated 2 weeks post-operatively

Secondary outcomes

  1. Length of stay

    Number of days to discharge (day 0 being the day of the operation)

    Time frame: Recorded at patient discharge (monitored by research team) and analysed at an expected time frame of 2 years (study end)

  2. Complications

    categorised by clavien-dindo (grade 1 to 5, higher score = worse)

    Time frame: 90 days

  3. adjuvant treatment

    percentage of patients receiving adjuvant chemotherapy, type and duration.

    Time frame: within 1 year of surgery

  4. Overall survival

    The length of time (in months) from day of diagnosis to death or last follow up

    Time frame: Analysis at 5 years from start of trial

  5. Disease free survival

    length of time (in months) from day of resection until diagnosis of recurrence or last follow up

    Time frame: Analysis at 5 years from start of trial

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Oct 2026, 66 months after the start.

Of 403 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 66 months is above that.

Counting every sponsor, half of 430 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2021
First posted
May 26, 2021
StartActual
Apr 6, 2021
Primary completionEst.
Oct 6, 2026
CompletionEst.
Oct 6, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04902352
Lead sponsor
University Hospital Birmingham NHS Foundation Trust
Responsible party
Nikolaos Chatzizacharias (Consultant HPB Surgeon, University Hospital Birmingham NHS Foundation Trust) — Principal investigator
First posted
May 26, 2021
Start date
Apr 6, 2021
Primary completion
Oct 6, 2026 (estimated)
Completion
Oct 6, 2026 (estimated)
Last update
Nov 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion